Covering the entire coagulation cascade, these deficient plasmas are used in combination with a selected PT and APTT reagent to determine specific factor activity in citrated plasma on ACL TOP systems. Includes a full range of factor deficient immunodeficient plasmas with < 1% residual activity and 24-hour on-board stability, reducing reagent waste. The liquid, ready-to-use FXIII antigen is fully automated, adding convenience compared to the manual, less specific clot solubility method.